Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1211-1216

  Kromdijk, Wiete ^a   Mulder, Jan W ^a   Rosing, Hilde ^a   Smit, Patrick M ^a   Beijnen, Jos H ^a,b   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

HIV; Non nucleoside reverse transcriptase inhibitors; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLASMA PROTEIN; RALTEGRAVIR; SAQUINAVIR; TENOFOVIR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; FEMALE; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PLASMA PROTEIN BINDING; TANDEM MASS SPECTROMETRY; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; BLOOD CHEMICAL ANALYSIS; DESICCATION; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PLASMA; SPECIMEN HANDLING;

EID: 84859571569     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks011     Document Type: Article

References (19)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/globalreport/global_report.htm (15 October 2011, date last accessed).
2. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ (15 October 2011, date last accessed).
3. European AIDS Clinical Society. Guidelines for Treatment of HIV Infected Adults in Europe, Version 6.0, October 2011. http://www.europeanaidsclinicalsociety.org/guidelines.asp (24 October 2011, date last accessed).
4. De Vries-Sluijs T, Dieleman JP, Arts D et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599-605.
5. Leth FV, Kappelhoff BS, Johnson D et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22: 232-9.
6. Burger DM. The role of therapeutic drug monitoring in pediatric HIV/AIDS. Ther Drug Monit 2010; 32: 269-72.
7. Edelbroek PM, van der Heijden J, Stolk LML. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009; 31: 327-36.
8. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis 2010; 2: 1385-95.
9. Li W, Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr 2010; 24: 49-65.
10. ter Heine R, Rosing H, van Gorp ECM et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 205-12.
11. ter Heine R, Alderden-los CG, Rosing H et al. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 2505-14.
12. Clinical and Laboratory Standards Institute. Method Comparison and Bias Estimation Using Patient Samples-Second Edition (Interim Revision): Approved Guideline EP09-A2-IR. CLSI, Wayne, PA, USA, 2005.
13. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-35.
14. Purves WK, Sadava D, Gordon H et al. Life: The Science of Biology. Sunderland: Sinauer Associates, 2004.
15. Bland J, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
16. Van Schooneveld T, Swindells S, Nelson SR et al. Clinical evaluation of a dried blood spot assay for atazanavir. Antimicrob Agents Chemother 2010; 54: 4124-8.
17. Koal T, Burhenne H, Ramling R et al. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 2995-3001.
18. Meesters RJW, van Kampen JJ, Reedijk ML et al. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Anal Bioanal Chem 2010; 398: 319-28.
19. ter Heine R, Mulder JW, van Gorp EC et al. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis 2011; 3: 1093-7.